EP3679971A1 — Nasal drug delivery device
Assigned to Impel Pharmaceuticals Inc · Expires 2020-07-15 · 6y expired
What this patent protects
A compound delivery device for delivering a plume derived from a propellant and a drug formulation. The propelled intranasal dosage form is deposited within the olfactory region of the nasal cavity. The device has an air compression chamber and a manual pressure actuator for obta…
USPTO Abstract
A compound delivery device for delivering a plume derived from a propellant and a drug formulation. The propelled intranasal dosage form is deposited within the olfactory region of the nasal cavity. The device has an air compression chamber and a manual pressure actuator for obtaining compressed air in the chamber. A trigger valve controls the flow of compressed air from the chamber to a diffuser and thence to a drug chamber which is configured to hold the drug formulation. The resulting aerosolized intra-nasal dosage form passes through a nozzle thus delivering a plume to the olfactory region of a user's nasal cavity.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.